Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beclomethasone dipropionate + salmeterol is a fixed-dose combination inhaled medication used primarily for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It combines two active ingredients: - Beclomethasone dipropionate, an inhaled corticosteroid that exerts anti-inflammatory effects by suppressing the activity of various inflammatory cells and mediators in the airways, thereby reducing airway inflammation. - Salmeterol, a long-acting beta2-adrenergic agonist (LABA) that acts as a bronchodilator by stimulating beta2 receptors in bronchial smooth muscle, leading to prolonged relaxation of airway muscles and improved airflow. This combination is indicated for patients whose asthma or COPD is not adequately controlled with inhaled corticosteroids alone. The use of both agents together provides synergistic benefits—reducing inflammation while also improving bronchodilation and symptom control[5][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beclomethasone dipropionate + salmeterol.